REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 28th, 2024 • Avalo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 28th, 2024 Company IndustryThis Registration Rights Agreement (this “Agreement”) is dated as of March [__], 2024, by and among Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2024 • Avalo Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 28th, 2024 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 27, 2024, by and among Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among AVALO THERAPEUTICS INC., PROJECT ATHENS MERGER SUB, INC., SECOND PROJECT ATHENS MERGER SUB, LLC, ALMATABIO, INC., and THE SECURITYHOLDERS’ REPRESENTATIVE IDENTIFIED HEREIN Dated as of March...Merger Agreement • March 28th, 2024 • Avalo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 28th, 2024 Company Industry JurisdictionThis Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of March 27, 2024, by and among Avalo Therapeutics, Inc., a Delaware corporation (“Parent”), Project Athens Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), Second Project Athens Merger Sub, LLC., a Delaware limited liability company and a wholly owned Subsidiary of Parent (“Second Merger Sub”), AlmataBio, Inc., a Delaware corporation (the “Company”), and Patrick Crutcher, (the “Securityholders’ Representative”) solely in his capacity as the representative agent and attorney-in-fact of the holders of securities in the Company (the “Securityholders”, and each of them, a “Securityholder”). Terms with initial capitalized letters used herein (including in the immediately preceding sentence) and not otherwise defined herein have the meanings set forth in Section 8.01 hereof.